Effect on fasting plasma glucose (FPG) of once daily oral administration during 28 days of O304 suspension in subjects with Type 2 Diabetes (T2D). A single-centre, randomised, parallel-group, double-blinded, placebo controlled Phase IIa study (TELLUS)
Latest Information Update: 12 Jan 2019
At a glance
- Drugs ATX 304 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Proof of concept; Therapeutic Use
- Acronyms TELLUS
- Sponsors Betagenon
- 21 Oct 2017 Status changed from recruiting to completed.
- 19 Sep 2016 New trial record